Recall Ledger

Gemcitabine Injection recall (McKesson)

DrugClass IIOngoing

Summary: McKesson is recalling Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01. Reason: Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

What is being recalled

Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01

Why

Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.

How serious is it

Class II is the middle level: using or being exposed to this product may cause temporary or medically reversible health problems, and the chance of serious harm is remote.

Where it was sold

Nationwide within the United States

How to tell if yours is affected

Lot #: CB0046, Exp. Date 06/2027

What to do

Check the product name, lot number and expiration date on your package against the codes above. If they match, do not stop taking a prescription medicine without talking to your doctor or pharmacist first; ask them about a replacement. Return or dispose of the product as your pharmacy advises.

Recall facts

Recall numberD-0714-2026
CategoryDrug
AgencyU.S. Food and Drug Administration (FDA)
SeverityClass II
StatusOngoing
Recall startedJune 10, 2026
ReportedJuly 8, 2026
CompanyMcKesson
Company locationIrving, TX, United States
Initiated byVoluntary: Firm initiated
Quantity74 units

More recalls from McKesson · all drug recalls · recalls from June 2026

Official FDA record